Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
about
Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathyPostprandial Hyperlipidemia and Remnant Lipoproteins.Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.Correlation between Traditional Chinese Medicine Constitution and Dyslipidemia: A Systematic Review and Meta-Analysis.A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
P2860
Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Bezafibrate for the treatment ...... e BIP randomized control trial
@ast
Bezafibrate for the treatment ...... e BIP randomized control trial
@en
type
label
Bezafibrate for the treatment ...... e BIP randomized control trial
@ast
Bezafibrate for the treatment ...... e BIP randomized control trial
@en
prefLabel
Bezafibrate for the treatment ...... e BIP randomized control trial
@ast
Bezafibrate for the treatment ...... e BIP randomized control trial
@en
P2093
P2860
P1476
Bezafibrate for the treatment ...... e BIP randomized control trial
@en
P2093
Alexander Tenenbaum
BIP Study Group
Enrique Z Fisman
Ilan Goldenberg
Nir Shlomo
Robert Klempfner
Sagit Benzekry
Yaron Arbel
P2860
P2888
P356
10.1186/S12933-016-0332-6
P407
P50
P577
2016-01-22T00:00:00Z
P5875
P6179
1009338991